Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRAP1 | Q12931 | 17/20 | 0.43 |
| ▸ | HSP90B1 | P14625 | 12/20 | 0.43 |
| ▸ | HSP90AA1 | P07900 | 6/20 | 0.43 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.32 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.32 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23498154 | 0.89 | TRAP1 (0.43) | TRAP1HSP90B1HSP90AA1ADORA2ATLR7 | |
| SCHEMBL29723515 | 0.89 | TRAP1 (0.43) | TRAP1HSP90B1HSP90AA1ADORA2ATLR7 | |
| SCHEMBL23991255 | 0.87 | TLR7 (0.36) | TRAP1HSP90B1HSP90AA1TLR7 | |
| SCHEMBL23629410 | 0.86 | HSP90AA1 (0.31) | TRAP1HSP90B1HSP90AA1 | |
| SCHEMBL872294 | 0.73 | TRAP1 (0.55) | TRAP1HSP90B1HSP90AA1ADORA2ATLR7 | |
| SCHEMBL23629388 | 0.71 | TRAP1 (0.53) | TRAP1HSP90B1HSP90AA1ADORA2A | |
| SCHEMBL8673254 | 0.70 | TRAP1 (0.52) | TRAP1HSP90B1HSP90AA1ADORA2ATLR7 | |
| SCHEMBL17425127 | 0.68 | DAO (0.31) | — | |
| SCHEMBL5173890 | 0.66 | TRAP1 (0.53) | TRAP1HSP90B1HSP90AA1ADORA2ATLR7 | |
| SCHEMBL4551932 | 0.64 | TRAP1 (0.54) | TRAP1HSP90B1HSP90AA1ADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240208999-A1 | HETEROCYCLIC COMPOUND | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2024-06-27 | — | — | US | disclosed |
| US-20240208999-A1 | HETEROCYCLIC COMPOUND | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2024-06-27 | — | — | US | disclosed |
| US-20240208999-A1 | HETEROCYCLIC COMPOUND | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2024-06-27 | — | — | US | disclosed |
| US-11932657-B2 | Heterocyclic compound | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2024-03-19 | — | — | US | disclosed |
| US-20210340157-A1 | HETEROCYCLIC COMPOUND | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2021-11-04 | — | — | US | disclosed |
| US-20210340157-A1 | HETEROCYCLIC COMPOUND | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2021-11-04 | — | — | US | disclosed |
| EP-3847176-A1 | HETEROCYCLIC COMPOUND | Otsuka Pharmaceutical Co., Ltd. (JP) | 2021-07-14 | — | — | EP | disclosed |
| CN-112654627-A | Heterocyclic compounds | 大塚制药株式会社 | 2021-04-13 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210340157-A1 | HETEROCYCLIC COMPOUND | AHR, PDGFRA, PDGFRB | TRAP1 1693/4885HSP90B1 1897/4885HSP90AA1 1394/4885 |
| US-11932657-B2 | Heterocyclic compound | AHR, PDGFRA, PDGFRB | TRAP1 1693/4885HSP90B1 1897/4885HSP90AA1 1394/4885 |
| US-20240208999-A1 | HETEROCYCLIC COMPOUND | AHR, PDGFRA, PDGFRB | TRAP1 1693/4885HSP90B1 1897/4885HSP90AA1 1394/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.